<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838121</url>
  </required_header>
  <id_info>
    <org_study_id>98-1150A3</org_study_id>
    <nct_id>NCT02838121</nct_id>
  </id_info>
  <brief_title>Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy</brief_title>
  <official_title>Investigation on the Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy: A Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mel Shiuann-Sheng Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Periprosthetic bone loss caused by stress-shielding effect, a phenomenon of bone atrophy
      under mechanical unloading after THR implantation, further compromises the longevity of
      implant. The prospective randomized study is aimed to investigate the periprosthetic bone
      loss after primary total hip replacements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, open-label clinical trial. The study will be
      performed in patients after obtaining informed consent. Group assignment is by drawing a
      sealed envelops based on random table. (1) Group 1: Experimental group 30 cases, AclastaÂ®
      (Zoledronic acid 5mg/100ml) is given intravenously on the 4th postoperative day and one year
      after the total hip replacement, (2) Group 2: Control group, 30 cases, no bisphosphonate is
      given to the patients. Only the unilateral coxarthrosis will be recruited for the study.
      Patients will be analyzed with (1) DXA study (2) Clinical assessment (Harris hip score and
      SF-12) (3) X-ray (4) serum marker of bone turnover. Patients will be scheduled for specified
      examinations preoperatively, postoperatively 6 weeks, 3 months, 6 months, 12 months, and 24
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density [g/cm2] of the 7 Gruen zones</measure>
    <time_frame>5 years</time_frame>
    <description>bone mineral density measured by dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bone mineral density change relative to the baseline values of the 7 Gruen zones</measure>
    <time_frame>5 years</time_frame>
    <description>bone mineral density measured by dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>implant loosening or migration</measure>
    <time_frame>5 years</time_frame>
    <description>check the implant position by serial standard X ray follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum alkaline phosphatase</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum calcium level</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum phosphate level</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum osteocalcin level</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum N-telopeptide procollagen level</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine level</measure>
    <time_frame>5 years</time_frame>
    <description>renal function and glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum alanine aminotransferase level</measure>
    <time_frame>5 years</time_frame>
    <description>liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum aspartate aminotransferase level</measure>
    <time_frame>5 years</time_frame>
    <description>liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>harris hip score</measure>
    <time_frame>5 years</time_frame>
    <description>hip function measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short form-12</measure>
    <time_frame>5 years</time_frame>
    <description>life quality measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of California Los Angeles Activity Score</measure>
    <time_frame>5 years</time_frame>
    <description>functional and activity evaluation, 10 point scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Prevention of BMD Loss After THR</condition>
  <condition>Serum Markers of Bone Turnover</condition>
  <condition>Functional Outcomes</condition>
  <arm_group>
    <arm_group_label>Aclasta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclasta IV once annual for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclasta</intervention_name>
    <description>Aclasta once annually for 2 years</description>
    <arm_group_label>Aclasta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No IV aclasta</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female,between 35 and 85 years of age

          2. Indicated for Total hip replacement for various hip diseases

          3. Has preoperative DXA study within 3 months before the total hip replacement procedure
             or willing to receive preoperative DXA study as a baseline comparison

          4. Signed written informed consent

          5. Standard transgluteal approach for total hip replacement using Zimmer Triology Cup and
             Versys Fiber Metal Taper Stem with metal to highly cross-linked polyethylene bearing
             surface

        Exclusion Criteria:

          1. Any prior use of intravenous bisphosphonate within the last 2 years

          2. Uncontrolled seizure disorders associated with falls

          3. A history of invasive malignancy of any organ system, treated or untreated, within the
             past five years; excluding, basal cell or squamous cell carcinoma of the skin, colonic
             polyps with non-invasive malignancy which have been removed

          4. Carcinoma in situ of the uterine cervix

          5. History of osteogenesis imperfecta, multiple myeloma, or Paget's disease

          6. Active primary hyperparathyroidism

          7. History of iritis or uveitis

          8. Self-reported history of diabetic nephropathy or retinopathy

          9. AST or ALT more than twice the upper limit of normal

         10. Alkaline phosphatase more than twice the upper limit of normal

         11. Serum calcium 2.75 mmol/L (11.0 mg/dL)

         12. Baseline renal insufficiency (calculated creatinine clearance 35 ml/min)

         13. History of hypersensitivity to bisphosphonates

         14. Use of any investigational drug(s) and/or devices within 30 days prior to
             randomization

         15. Any medical or psychiatric condition which, in the Investigator's opinion, would
             preclude the participant from adhering to the Protocol or completing the trial per
             protocol

         16. Use of hip protectors

         17. With implant or prosthesis on the contralateral hip joint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kweishan</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.AAOS.org</url>
    <description>American Academy of Orthopaedic Surgeons</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Mel Shiuann-Sheng Lee</investigator_full_name>
    <investigator_title>Clinical Professor, Chang Gung Memorial Hospital, Department of Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <keyword>bisphosphonate</keyword>
  <keyword>Total hip replacement</keyword>
  <keyword>functional outcomes</keyword>
  <keyword>bone mineral density</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

